Alpha DaRT Investigator Meeting in Las Vegas

Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)

Completion of Enrollment in 1st US Clinical Trial & Achievement of 1st Primary Objective

Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM

Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company

First Alpha DaRT Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial

Israeli medical device maker Alpha Tau raises $26 million to fund trials

Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round

Lela’s Story of her Cancer Treatment Journey that Brought her to Alpha DaRT

Alpha Tau Medical Announces Exclusive Distribution Arrangement with Medison Canada For Breakthrough